Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) has recently appointed Corleen Roche as its new Chief Financial Officer (CFO), effective from August 6th, 2025. Ms. Roche brings with her a wealth of experience in the biotech and life sciences industry, with over 30 years of executive financial leadership roles in publicly traded companies.
Ms. Roche's most recent role was as the CFO of CG Oncology, a late-stage clinical biopharmaceutical company. Her previous positions include CFO of Immunome, U.S. CFO at Biogen, North America CFO of CSL Behring, and various CFO roles within Sandoz, Wyeth, and Pfizer. Notably, during her career, Ms. Roche played key roles in preparing for commercial launches, including the first U.S. approved biosimilar, Zarxio®, the complex generic for multiple sclerosis, Glatopa™, and a pneumococcal conjugate vaccine, Prevnar 13®.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. The company has demonstrated promising clinical data across multiple solid tumors, and its AMTAGVI® is the first FDA-approved T cell therapy for a solid tumor indication.
As the new CFO, Ms. Roche expressed her excitement to join Iovance and her commitment to the company's patient-focused mission while achieving financial goals to build a profitable biotechnology company. Her appointment comes at an important stage in Iovance's first commercial launch, where the company is focusing on growing revenue, managing its balance sheet, and advancing its mission of developing and delivering novel therapies to patients with solid tumors. Following these announcements, the company's shares moved 7.49%, and are now trading at a price of $2.01. For more information, read the company's full 8-K submission here.
